Cell therapy developers face increasing demands to speed up safety testing while maintaining high standards of quality and regulatory compliance. Traditional culture-based methods for detecting mycoplasma and sterility issues are often slow and labor-intensive. PCR-based testing offers a faster, more flexible alternative that can improve the efficiency of safety assessments in cell therapy manufacturing.
This approach enables more reliable detection of contaminants, helping developers meet tight timelines without sacrificing accuracy. Thermo Fisher Scientific provides resources detailing how molecular testing techniques can modernize safety protocols in cell therapy development.
**Why this matters**
Accelerating safety testing is critical for bringing cell therapies to patients more quickly. PCR-based methods reduce turnaround times compared to conventional culture tests, supporting faster decision-making in manufacturing. Additionally, these molecular techniques help ensure compliance with regulatory standards by providing sensitive and dependable results, ultimately enhancing product safety and development efficiency.
Source: NewsData